https://pharminent.com/astrazeneca-and-bristol-myers-squibb-reported-to-have-held-mega-merger-talks/ 2026-08-03T16:53:54Z Pharminent en AstraZeneca and Bristol Myers Squibb Reported to Have Held Mega-Merger Talks 2026-08-03T16:52:43Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-august-3-2026/ 2026-08-03T15:44:12Z Pharminent en Strategic News Watch • August 3, 2026 2026-08-03T15:44:10Z Blog https://pharminent.com/parsortix-study-shows-promise-for-adc-target-detection/ 2026-08-03T15:41:32Z Pharminent en Parsortix study shows promise for ADC target detection 2026-08-03T10:54:03Z Blog https://pharminent.com/oncology/oncology-intelligence-digest-july-31-2026/ 2026-08-03T07:54:47Z Pharminent en Oncology Intelligence Digest • July 31, 2026 2026-08-03T07:54:45Z Blog https://pharminent.com/glp-1-competitive-market/glp-1-competitive-market-digest-weekly-july-31-2026/ 2026-08-03T07:52:59Z Pharminent en GLP-1 Competitive Market Digest • Weekly • July 31, 2026 2026-08-03T07:52:57Z Blog https://pharminent.com/market-access/market-access-intelligence-weekly-digest-july-31-2026/ 2026-08-03T07:51:10Z Pharminent en MARKET ACCESS INTELLIGENCE • Weekly Digest • July 31, 2026 2026-08-03T07:51:08Z Blog https://pharminent.com/novo-nordisks-ziltivekimab-misses-primary-endpoint-in-pivotal-cardiovascular-trial/ 2026-08-03T15:38:01Z Pharminent en Novo Nordisk's Ziltivekimab Misses Primary Endpoint in Pivotal Cardiovascular Trial 2026-08-01T01:25:56Z Blog https://pharminent.com/strategic-news-watch/strategic-news-watch-july-31-2026/ 2026-08-01T01:07:45Z Pharminent en Strategic News Watch • July 31, 2026 2026-08-01T01:07:43Z Blog